Key features and details
- Sensitivity: 10 ng/ml
- Range: 30 ng/ml - 1000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Quantitative
- Reacts with: Human
Product namePembrolizumab ELISA Kit
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15%
Sample typeSerum, Plasma
Range30 ng/ml - 1000 ng/ml
Sample specific recovery Sample type Average % Range Serum 85% - 115%
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Note: Pembrolizumab ELISA kit ab237652 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Pembrolizumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Storage instructionsStore at +4°C. Please refer to protocols.
Components 96 tests Assay Buffer 2 x 50ml HRP-conjugate Probe 1 x 12ml Micro ELISA Plate 1 unit Pembrolizumab Standard S1 1 x 0.3ml Pembrolizumab Standard S2 1 x 0.3ml Pembrolizumab Standard S3 1 x 0.3ml Pembrolizumab Standard S4 1 x 0.3ml Pembrolizumab Standard S5 1 x 0.3ml Pembrolizumab Standard S6 1 x 0.3ml Pembrolizumab Standard S7 1 x 0.3ml Plate sealers 2 units Stop Solution 1 x 12ml TMB substrate 1 x 12ml Wash buffer (20X) 1 x 50ml
RelevancePembrolizumab is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti-tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells.
ab237652 has been referenced in 1 publication.
- Gauckler P et al. Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma-A case report. J Clin Apher 35:227-230 (2020). PubMed: 32142176